J&J's Tecvayli shows promise as a second-line multiple myeloma treatment
New phase 3 data found that Johnson & Johnson's (JNJ) Tecvayli (teclistamab) as monotherapy led to better progression-free and overall survival in multiple myeloma patients as a second-line therapy compared to standard of care. The trial enrolled mostly...
Seeking Alpha